Study of VN-0200 in Japanese Healthy Adults and Elderly Subjects
Launched by DAIICHI SANKYO CO., LTD. · May 31, 2021
Trial Information
Current as of May 30, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Japanese
- • Healthy adults aged ≥20 and ≤50 years (Step 1) or healthy elderly aged ≥65 and ≤80 years (at the time of informed consent)
- • Body mass index (BMI) is ≥18.0 and \<30.0 kg/m\^2 (at screening)
- Exclusion Criteria:
- • Participants with a history of anaphylaxis or severe allergies due to food, medicine, insect bites, cosmetics, or vaccination
- • Having alcohol or drug dependence, etc.
About Daiichi Sankyo Co., Ltd.
Daiichi Sankyo Co., Ltd. is a global healthcare company headquartered in Tokyo, Japan, renowned for its commitment to innovative research and development in pharmaceuticals. With a rich history spanning over a century, the company focuses on delivering transformative treatments across various therapeutic areas, including oncology, cardiovascular disease, and infectious diseases. Daiichi Sankyo leverages cutting-edge science and technology to advance its drug development pipeline, emphasizing collaboration and partnership to enhance patient outcomes worldwide. Its dedication to improving global health is reflected in its extensive clinical trials, which aim to bring novel therapies to market and address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shinjuku Ku, Tokyo, Japan
Patients applied
Trial Officials
Clinical Study Leader
Study Director
Daiichi Sankyo
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials